uncovr

Alle Regionen

Alle Regionen Österreich Deutschland International

GlaxoSmithKline Pharma GmbH - Pressemeldungen

Alle Meldungen

09.09

GlaxoSmithKline Pharma GmbH GlaxoSmithKline

Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations

Issued: London, UK For media and investors only Download (PDF, 185.7KB) SWIFT-1 and SWIFT-2 phase III data show depemokimab delivered a statistically significant and clinically meaningful reduction in exacerbations over 52 weeks versus placebo...

Zur Pressemeldung auf www.gsk.com
06.09

GlaxoSmithKline Pharma GmbH GlaxoSmithKline

GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD

Issued: London, UK For media and investors only Download (PDF, 170.6KB) Primary endpoint met with a statistically significant and clinically meaningful reduction in annualised rate of moderate/severe exacerbations vs. placebo with data up to two...

Zur Pressemeldung auf www.gsk.com
03.09

GlaxoSmithKline Pharma GmbH GlaxoSmithKline

GSK aims to redefine the future of respiratory medicine at the European Respiratory Society International Congress

Issued: London, UK For media and investors only Download (PDF, 168.7KB) First presentation of SWIFT-1 and SWIFT-2 phase III trial data for ultra-long-acting biologic depemokimab in severe asthma GSK aspires to change the course of disease,...

Zur Pressemeldung auf www.gsk.com
29.08

GlaxoSmithKline Pharma GmbH GlaxoSmithKline

European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk

Issued: London, UK For media and investors only Download (PDF, 391.3KB) An estimated 20 million adults aged 50-59 in 30 European countries* have a medical condition that increases their risk for RSV disease 1-3 Authorisation helps protect this...

Zur Pressemeldung auf www.gsk.com
28.08

GlaxoSmithKline Pharma GmbH GlaxoSmithKline

GSK’s Nucala (mepolizumab) approved in Japan for treatment of adults with chronic rhinosinusitis with nasal polyps

Issued: London, UK For media and investors only Download (PDF, 255.2KB) Nucala is the first and only biologic in Japan with a four-weekly dosing schedule for this condition Chronic rhinosinusitis with nasal polyps (CRSwNP) exerts significant...

Zur Pressemeldung auf www.gsk.com
27.08

GlaxoSmithKline Pharma GmbH GlaxoSmithKline

Statement: Zantac (ranitidine) litigation – Delaware Supreme Court to review Superior Court’s Daubert decision

For media and investors only Issued: 27 August 2024, London UK Download (PDF, 123.0KB) GSK plc (LSE/NYSE: GSK) welcomes today’s decision by the Delaware Supreme Court that it will review the Delaware Superior Court’s decision allowing the...

Zur Pressemeldung auf www.gsk.com
20.08

GlaxoSmithKline Pharma GmbH GlaxoSmithKline

GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer

Issued: London, UK For media and investors only Download (PDF, 141.5KB) Regulatory designation based on promising early clinical evidence observed with GSK5764227 in this tumour type Breakthrough Therapy Designation aims to expedite development...

Zur Pressemeldung auf www.gsk.com
15.08

GlaxoSmithKline Pharma GmbH GlaxoSmithKline

Statement: Zantac (ranitidine) litigation – Florida State Court Daubert Ruling in Wilson case

For media and investors only Issued: 15 August 2024, London UK Download (PDF, 124.1KB) Florida State Court’s ruling finds in favour of GSK and other defendants, excluding plaintiff’s experts’ general and specific causation testimony that...

Zur Pressemeldung auf www.gsk.com
05.08

GlaxoSmithKline Pharma GmbH GlaxoSmithKline

Statement: Zantac (ranitidine) litigation – Joiner case

For media and investors only Issued: 5 August 2024, London UK Download (PDF, 126.9KB) Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer Verdict is consistent with the scientific consensus that...

Zur Pressemeldung auf www.gsk.com
01.08

GlaxoSmithKline Pharma GmbH GlaxoSmithKline

US FDA expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

For media and investors only Issued: London, UK Download (PDF, 181.9KB) Jemperli approval now includes MMRp/MSS tumours, which represent majority of endometrial cancer cases Jemperli plus chemotherapy demonstrated a statistically significant...

Zur Pressemeldung auf www.gsk.com

Wem folgen?

Verbund
Folgen
Finanzchef24
Folgen
BMW Österreich
Folgen

Mehr anzeigen

Trends

Weihnachten
Folgen
Tierschutz
Folgen
Produktivität
Folgen
Startup
Folgen
Artenschutz
Folgen
Streaming
Folgen
Cyber Security
Folgen

Mehr anzeigen

uncovr pure news - Die neue Art Presseinhalte zu recherchieren. Mehr Info